Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Sonstige Behandlungsmethoden gegen Neuroleptika‐induzierte Spätdyskinesien

Información

DOI:
https://doi.org/10.1002/14651858.CD000208.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 19 marzo 2018see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:
  1. Grupo Cochrane de Esquizofrenia

Copyright:
  1. Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Karla Soares‐Weiser

    Editorial & Methods Department, Cochrane, London, UK

  • John Rathbone

    Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Australia

  • Yusuke Ogawa

    Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan

  • Kiyomi Shinohara

    Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Japan

  • Hanna Bergman

    Correspondencia a: Cochrane Response, Cochrane, London, UK

    [email protected]

    [email protected]

Contributions of authors

Karla Soares‐Weiser (KSW) ‐ protocol development, searching, study selection, data extraction and assimilation, report writing ‐ all versions.

John Rathbone (JR ‐ helped update review in 2009

Hanna Bergman (HB) ‐ updated review in 2017

Sources of support

Internal sources

  • CAPES ‐ Ministry of Education, Brazil, Brazil.

  • Universidade Federal de Sao Paulo, Brazil, Brazil.

  • Cochrane Schizophrenia Group, UK.

  • Enhance Reviews Ltd., UK.

    Logistics support for Hanna Bergman for the 2016 update.

External sources

  • NIHR HTA Project Grant, reference number: 14/27/02, UK.

    Salary support for Hanna Bergman.
    Support for patient involvement consultation.

Declarations of interest

KSW is the Deputy Editor‐in‐Chief for Cochrane and Cochrane Innovations. When the NHIR HTA programme grant relevant to this review update was awarded, KSW was the Managing Director of Enhance Reviews Ltd.

JR ‐ none known.

HB worked for Enhance Reviews Ltd. during preparation of this review and was paid for her contribution to this review. Enhance Reviews Ltd. is a private company that performs systematic reviews of literature. HB works for Cochrane Response, an evidence consultancy linked to Cochrane that take commissions from healthcare guideline developers and policy makers.

Acknowledgements

The authors are indebted to Geoff Davies, Kirsten Mason, Carmel Meir and Leanne Roberts for assistance with this review.

We are especially grateful to the following trialists who provided additional material; Professor Jes Gerlach, Dr Tetsuo Matsunaga, Dr Jacques Mouret, Dr Jan Sikora, Dr Krishna Viddadi and Dr Adam Wolkin. Thank you to John McGrath for protocol development, data extraction and assimilation and report writing. John authored this review from 1997‐2002.

For the 2017 update, we wish to thank Rosie Asher (RA) and Antonio Grande (AG) for screening literature and helping with data extraction, Farhad Sokraneh for carrying out the trial search and helping to find full‐text papers, Ben Gray for writing the Plain language summary, and Nicholas Henschke and Loukia Spineli for assistance with preparing the report. We also acknowledge Dawn‐Marie Walker, Ruth Sayers, Megan Lees, and Vanessa Pinfold from McPin Foundation for organising and holding the public and patient involvement consultation with TD service users that contributed to selecting outcomes for the 'Summary of findings' tables and to guide future research. Finally, we wish to thank Sai Zhao and Jun Xia for assessing and extracting data from articles in Chinese.

The Cochrane Schizophrenia Group Editorial Base in Nottingham produces and maintains standard text for use in the Methods sections of their reviews. We have used this text as the basis of what appears here and adapted it as required.

Version history

Published

Title

Stage

Authors

Version

2018 Mar 19

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia

Review

Karla Soares‐Weiser, John Rathbone, Yusuke Ogawa, Kiyomi Shinohara, Hanna Bergman

https://doi.org/10.1002/14651858.CD000208.pub2

2003 Apr 22

Miscellaneous treatments for neuroleptic‐induced tardive dyskinesia

Review

Karla Soares‐Weiser, Claire B Irving, John Rathbone

https://doi.org/10.1002/14651858.CD000208

Differences between protocol and review

The protocol as published with this review has evolved over time. The revisions of protocol are in line with the development of RevMan and in keeping with Cochrane guidance. We think the revisions have greatly improved and enhanced this review. We do not think, however, that it has materially affected our conduct of the review or interpretation of the results.

There was a substantial update to the protocol in the 2016 review update with main changes being to:

  1. change the title from 'Miscellaneous treatments for neuroleptic‐induced tardive dyskinesia';

  2. broaden the inclusion criteria by adding the comparison: 'Any intervention compared with any other intervention for the treatment of tardive dyskinesia';

  3. rename and update list of important outcomes following consultation with consumers;

  4. prioritise comparisons for 'Summary of findings' tables: 'Summary of findings' tables were created only for those comparisons that: 1) included more than 60 participants, or 2) included more than one trial;

  5. we analysed outcomes using risk ratios (see Methods) ‐ rather than odds ratios.

The previous methods are reproduced in Appendix 1; Appendix 2, and Appendix 3.

Keywords

MeSH

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Message from one of the participants of the Public and patient involvement consultation of service user perspectives on tardive dyskinesia research.
Figuras y tablas -
Figure 1

Message from one of the participants of the Public and patient involvement consultation of service user perspectives on tardive dyskinesia research.

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
Figuras y tablas -
Figure 2

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 3

'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Study flow diagram for 2015 and 2017 searches.
Figuras y tablas -
Figure 4

Study flow diagram for 2015 and 2017 searches.

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.
Figuras y tablas -
Analysis 1.1

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.
Figuras y tablas -
Analysis 1.2

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ medium term.
Figuras y tablas -
Analysis 1.3

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ medium term.

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 4 Tardive dyskinesia: 3. Average endpoint scale score (Simpson scale, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 1.4

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 4 Tardive dyskinesia: 3. Average endpoint scale score (Simpson scale, high=poor) ‐ medium term.

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 5 Tardive dyskinesia: Average scale change scores (various scales, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 1.5

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 5 Tardive dyskinesia: Average scale change scores (various scales, high=poor) ‐ medium term.

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 6 Mental state: Deterioration ‐ medium term.
Figuras y tablas -
Analysis 1.6

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 6 Mental state: Deterioration ‐ medium term.

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 7 Adverse events ‐ medium term.
Figuras y tablas -
Analysis 1.7

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 7 Adverse events ‐ medium term.

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 8 Leaving the study early ‐ medium term.
Figuras y tablas -
Analysis 1.8

Comparison 1 ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO, Outcome 8 Leaving the study early ‐ medium term.

Comparison 2 ALKALOID ‐ L‐STEPHOLIDINE (SPD) versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.
Figuras y tablas -
Analysis 2.1

Comparison 2 ALKALOID ‐ L‐STEPHOLIDINE (SPD) versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.

Comparison 2 ALKALOID ‐ L‐STEPHOLIDINE (SPD) versus PLACEBO, Outcome 2 Mental state: 1. Average endpoint scale score (BPRS, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 2.2

Comparison 2 ALKALOID ‐ L‐STEPHOLIDINE (SPD) versus PLACEBO, Outcome 2 Mental state: 1. Average endpoint scale score (BPRS, high=poor) ‐ medium term.

Comparison 2 ALKALOID ‐ L‐STEPHOLIDINE (SPD) versus PLACEBO, Outcome 3 Adverse events: any adverse events ‐ medium term.
Figuras y tablas -
Analysis 2.3

Comparison 2 ALKALOID ‐ L‐STEPHOLIDINE (SPD) versus PLACEBO, Outcome 3 Adverse events: any adverse events ‐ medium term.

Comparison 2 ALKALOID ‐ L‐STEPHOLIDINE (SPD) versus PLACEBO, Outcome 4 Leaving the study early ‐ medium term.
Figuras y tablas -
Analysis 2.4

Comparison 2 ALKALOID ‐ L‐STEPHOLIDINE (SPD) versus PLACEBO, Outcome 4 Leaving the study early ‐ medium term.

Comparison 3 ALKALOID ‐ PAPAVERINE versus PLACEBO, Outcome 1 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 3.1

Comparison 3 ALKALOID ‐ PAPAVERINE versus PLACEBO, Outcome 1 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term.

Comparison 4 AMINO ACID ‐ BRANCHED‐CHAIN AMINO ACID (BCAA) versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term.
Figuras y tablas -
Analysis 4.1

Comparison 4 AMINO ACID ‐ BRANCHED‐CHAIN AMINO ACID (BCAA) versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term.

Comparison 4 AMINO ACID ‐ BRANCHED‐CHAIN AMINO ACID (BCAA) versus PLACEBO, Outcome 2 Tardive dyskinesia: 1. Not any improvement ‐ short term.
Figuras y tablas -
Analysis 4.2

Comparison 4 AMINO ACID ‐ BRANCHED‐CHAIN AMINO ACID (BCAA) versus PLACEBO, Outcome 2 Tardive dyskinesia: 1. Not any improvement ‐ short term.

Comparison 4 AMINO ACID ‐ BRANCHED‐CHAIN AMINO ACID (BCAA) versus PLACEBO, Outcome 3 Tardive dyskinesia: 2. Deterioration ‐ short term.
Figuras y tablas -
Analysis 4.3

Comparison 4 AMINO ACID ‐ BRANCHED‐CHAIN AMINO ACID (BCAA) versus PLACEBO, Outcome 3 Tardive dyskinesia: 2. Deterioration ‐ short term.

Comparison 4 AMINO ACID ‐ BRANCHED‐CHAIN AMINO ACID (BCAA) versus PLACEBO, Outcome 4 Tardive dyskinesia: Average endpoint score (Simpson scale, high=poor) ‐ short term.
Figuras y tablas -
Analysis 4.4

Comparison 4 AMINO ACID ‐ BRANCHED‐CHAIN AMINO ACID (BCAA) versus PLACEBO, Outcome 4 Tardive dyskinesia: Average endpoint score (Simpson scale, high=poor) ‐ short term.

Comparison 4 AMINO ACID ‐ BRANCHED‐CHAIN AMINO ACID (BCAA) versus PLACEBO, Outcome 5 Leaving the study early ‐ short term.
Figuras y tablas -
Analysis 4.5

Comparison 4 AMINO ACID ‐ BRANCHED‐CHAIN AMINO ACID (BCAA) versus PLACEBO, Outcome 5 Leaving the study early ‐ short term.

Comparison 5 AMINO ACID ‐ PHENYLALANINE versus PLACEBO, Outcome 1 Leaving the study early ‐ short term.
Figuras y tablas -
Analysis 5.1

Comparison 5 AMINO ACID ‐ PHENYLALANINE versus PLACEBO, Outcome 1 Leaving the study early ‐ short term.

Comparison 6 ANTIDEPRESSANT (MAO‐B inhibitor) ‐ SELEGILINE versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.
Figuras y tablas -
Analysis 6.1

Comparison 6 ANTIDEPRESSANT (MAO‐B inhibitor) ‐ SELEGILINE versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.

Comparison 6 ANTIDEPRESSANT (MAO‐B inhibitor) ‐ SELEGILINE versus PLACEBO, Outcome 2 Leaving the study early ‐ medium term.
Figuras y tablas -
Analysis 6.2

Comparison 6 ANTIDEPRESSANT (MAO‐B inhibitor) ‐ SELEGILINE versus PLACEBO, Outcome 2 Leaving the study early ‐ medium term.

Comparison 7 ANTIDEPRESSANT (MAOI) ISOCARBOXAZID versus PROCYCLIDINE, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ long term.
Figuras y tablas -
Analysis 7.1

Comparison 7 ANTIDEPRESSANT (MAOI) ISOCARBOXAZID versus PROCYCLIDINE, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ long term.

Comparison 7 ANTIDEPRESSANT (MAOI) ISOCARBOXAZID versus PROCYCLIDINE, Outcome 2 Tardive dyskinesia: 1. Not any improvement ‐ long term.
Figuras y tablas -
Analysis 7.2

Comparison 7 ANTIDEPRESSANT (MAOI) ISOCARBOXAZID versus PROCYCLIDINE, Outcome 2 Tardive dyskinesia: 1. Not any improvement ‐ long term.

Comparison 7 ANTIDEPRESSANT (MAOI) ISOCARBOXAZID versus PROCYCLIDINE, Outcome 3 Adverse effects ‐ long term.
Figuras y tablas -
Analysis 7.3

Comparison 7 ANTIDEPRESSANT (MAOI) ISOCARBOXAZID versus PROCYCLIDINE, Outcome 3 Adverse effects ‐ long term.

Comparison 7 ANTIDEPRESSANT (MAOI) ISOCARBOXAZID versus PROCYCLIDINE, Outcome 4 Leaving the study early ‐ long term.
Figuras y tablas -
Analysis 7.4

Comparison 7 ANTIDEPRESSANT (MAOI) ISOCARBOXAZID versus PROCYCLIDINE, Outcome 4 Leaving the study early ‐ long term.

Comparison 8 ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO, Outcome 1 Tardive dyskinesia: No clinically important improvement (short term).
Figuras y tablas -
Analysis 8.1

Comparison 8 ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO, Outcome 1 Tardive dyskinesia: No clinically important improvement (short term).

Comparison 8 ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO, Outcome 2 Tardive dyskinesia: Not any improvement (short term).
Figuras y tablas -
Analysis 8.2

Comparison 8 ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO, Outcome 2 Tardive dyskinesia: Not any improvement (short term).

Comparison 8 ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO, Outcome 3 Tardive dyskinesia: Deterioration (short term).
Figuras y tablas -
Analysis 8.3

Comparison 8 ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO, Outcome 3 Tardive dyskinesia: Deterioration (short term).

Comparison 8 ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO, Outcome 4 Tardive dyskinesia: Average change score (AIMS, high=poor) (short term).
Figuras y tablas -
Analysis 8.4

Comparison 8 ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO, Outcome 4 Tardive dyskinesia: Average change score (AIMS, high=poor) (short term).

Comparison 8 ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO, Outcome 5 General mental state: Deterioration (short term).
Figuras y tablas -
Analysis 8.5

Comparison 8 ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO, Outcome 5 General mental state: Deterioration (short term).

Comparison 8 ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO, Outcome 6 General mental state: Average change score (BPRS, high=poor) (short term).
Figuras y tablas -
Analysis 8.6

Comparison 8 ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO, Outcome 6 General mental state: Average change score (BPRS, high=poor) (short term).

Comparison 9 ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. Average endpoint score (AIMS, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 9.1

Comparison 9 ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. Average endpoint score (AIMS, high=poor) ‐ medium term.

Comparison 9 ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO, Outcome 2 Tardive dyskinesia: 1. Average change score (hyperkinesia subscale of the SHRS , high=poor) ‐ medium term.
Figuras y tablas -
Analysis 9.2

Comparison 9 ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO, Outcome 2 Tardive dyskinesia: 1. Average change score (hyperkinesia subscale of the SHRS , high=poor) ‐ medium term.

Comparison 9 ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO, Outcome 3 Leaving the study early ‐ medium term.
Figuras y tablas -
Analysis 9.3

Comparison 9 ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO, Outcome 3 Leaving the study early ‐ medium term.

Comparison 9 ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO, Outcome 4 Adverse effects ‐ medium term.
Figuras y tablas -
Analysis 9.4

Comparison 9 ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO, Outcome 4 Adverse effects ‐ medium term.

Comparison 9 ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO, Outcome 5 Mental state: deterioration ‐ medium term.
Figuras y tablas -
Analysis 9.5

Comparison 9 ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO, Outcome 5 Mental state: deterioration ‐ medium term.

Comparison 10 ANTIHISTAMINE ‐ CYPROHEPTADINE versus PLACEBO, Outcome 1 Tardive dyskinesia: 2. Not any improvement ‐ short term.
Figuras y tablas -
Analysis 10.1

Comparison 10 ANTIHISTAMINE ‐ CYPROHEPTADINE versus PLACEBO, Outcome 1 Tardive dyskinesia: 2. Not any improvement ‐ short term.

Comparison 10 ANTIHISTAMINE ‐ CYPROHEPTADINE versus PLACEBO, Outcome 2 Tardive dyskinesia: 3. Deterioration ‐ short term.
Figuras y tablas -
Analysis 10.2

Comparison 10 ANTIHISTAMINE ‐ CYPROHEPTADINE versus PLACEBO, Outcome 2 Tardive dyskinesia: 3. Deterioration ‐ short term.

Comparison 10 ANTIHISTAMINE ‐ CYPROHEPTADINE versus PLACEBO, Outcome 3 Adverse events ‐ short term.
Figuras y tablas -
Analysis 10.3

Comparison 10 ANTIHISTAMINE ‐ CYPROHEPTADINE versus PLACEBO, Outcome 3 Adverse events ‐ short term.

Comparison 10 ANTIHISTAMINE ‐ CYPROHEPTADINE versus PLACEBO, Outcome 4 Leaving the study early ‐ short term.
Figuras y tablas -
Analysis 10.4

Comparison 10 ANTIHISTAMINE ‐ CYPROHEPTADINE versus PLACEBO, Outcome 4 Leaving the study early ‐ short term.

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 1 Tardive dyskinesia: No clinically important improvement (medium term).
Figuras y tablas -
Analysis 11.1

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 1 Tardive dyskinesia: No clinically important improvement (medium term).

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 2 Tardive dyskinesia: Not any improvement (medium term).
Figuras y tablas -
Analysis 11.2

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 2 Tardive dyskinesia: Not any improvement (medium term).

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 3 Tardive dyskinesia: Average endpoint score (AIMS, high=poor) (medium term).
Figuras y tablas -
Analysis 11.3

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 3 Tardive dyskinesia: Average endpoint score (AIMS, high=poor) (medium term).

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 4 General mental state: Average endpoint score (BPRS, high=poor) (medium term).
Figuras y tablas -
Analysis 11.4

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 4 General mental state: Average endpoint score (BPRS, high=poor) (medium term).

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 5 Adverse effects: Any adverse effects (TESS, high=poor) (medium term).
Figuras y tablas -
Analysis 11.5

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 5 Adverse effects: Any adverse effects (TESS, high=poor) (medium term).

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 6 Adverse effects: Parkinsonism ‐ Average endpoint score (RSESE) (medium term).
Figuras y tablas -
Analysis 11.6

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 6 Adverse effects: Parkinsonism ‐ Average endpoint score (RSESE) (medium term).

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 7 Global state: Average endpoint score (CGI, high=poor) (medium term).
Figuras y tablas -
Analysis 11.7

Comparison 11 ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO, Outcome 7 Global state: Average endpoint score (CGI, high=poor) (medium term).

Comparison 12 ANXIOLYTIC ‐ BUSPIRONE versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.
Figuras y tablas -
Analysis 12.1

Comparison 12 ANXIOLYTIC ‐ BUSPIRONE versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.

Comparison 12 ANXIOLYTIC ‐ BUSPIRONE versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.
Figuras y tablas -
Analysis 12.2

Comparison 12 ANXIOLYTIC ‐ BUSPIRONE versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.

Comparison 12 ANXIOLYTIC ‐ BUSPIRONE versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 12.3

Comparison 12 ANXIOLYTIC ‐ BUSPIRONE versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term.

Comparison 12 ANXIOLYTIC ‐ BUSPIRONE versus PLACEBO, Outcome 4 Leaving the study early ‐ medium term.
Figuras y tablas -
Analysis 12.4

Comparison 12 ANXIOLYTIC ‐ BUSPIRONE versus PLACEBO, Outcome 4 Leaving the study early ‐ medium term.

Comparison 13 COGNITIVE ENHANCER ‐ PIRACETAM versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. Average endpoint score (ESRS, high=poor) ‐ short term.
Figuras y tablas -
Analysis 13.1

Comparison 13 COGNITIVE ENHANCER ‐ PIRACETAM versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. Average endpoint score (ESRS, high=poor) ‐ short term.

Comparison 13 COGNITIVE ENHANCER ‐ PIRACETAM versus PLACEBO, Outcome 2 Parkinsonism: 1. Average endpoint score (ESRS, high=poor) ‐ short term.
Figuras y tablas -
Analysis 13.2

Comparison 13 COGNITIVE ENHANCER ‐ PIRACETAM versus PLACEBO, Outcome 2 Parkinsonism: 1. Average endpoint score (ESRS, high=poor) ‐ short term.

Comparison 13 COGNITIVE ENHANCER ‐ PIRACETAM versus PLACEBO, Outcome 3 Leaving the study early ‐ short term.
Figuras y tablas -
Analysis 13.3

Comparison 13 COGNITIVE ENHANCER ‐ PIRACETAM versus PLACEBO, Outcome 3 Leaving the study early ‐ short term.

Comparison 13 COGNITIVE ENHANCER ‐ PIRACETAM versus PLACEBO, Outcome 4 Global state: Average endpoint score (CGI, high=poor) ‐ short term.
Figuras y tablas -
Analysis 13.4

Comparison 13 COGNITIVE ENHANCER ‐ PIRACETAM versus PLACEBO, Outcome 4 Global state: Average endpoint score (CGI, high=poor) ‐ short term.

Comparison 14 COGNITIVE ENHANCER/STIMULANT ‐ PEMOLINE versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.
Figuras y tablas -
Analysis 14.1

Comparison 14 COGNITIVE ENHANCER/STIMULANT ‐ PEMOLINE versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.

Comparison 14 COGNITIVE ENHANCER/STIMULANT ‐ PEMOLINE versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.
Figuras y tablas -
Analysis 14.2

Comparison 14 COGNITIVE ENHANCER/STIMULANT ‐ PEMOLINE versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.

Comparison 14 COGNITIVE ENHANCER/STIMULANT ‐ PEMOLINE versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 14.3

Comparison 14 COGNITIVE ENHANCER/STIMULANT ‐ PEMOLINE versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term.

Comparison 14 COGNITIVE ENHANCER/STIMULANT ‐ PEMOLINE versus PLACEBO, Outcome 4 Leaving the study early ‐ medium term.
Figuras y tablas -
Analysis 14.4

Comparison 14 COGNITIVE ENHANCER/STIMULANT ‐ PEMOLINE versus PLACEBO, Outcome 4 Leaving the study early ‐ medium term.

Comparison 15 ENZYME INHIBITOR ‐ VMAT2 INHIBITORS versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.
Figuras y tablas -
Analysis 15.1

Comparison 15 ENZYME INHIBITOR ‐ VMAT2 INHIBITORS versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.

Comparison 15 ENZYME INHIBITOR ‐ VMAT2 INHIBITORS versus PLACEBO, Outcome 2 Tardive dyskinesia: 3. Average change score (AIMS, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 15.2

Comparison 15 ENZYME INHIBITOR ‐ VMAT2 INHIBITORS versus PLACEBO, Outcome 2 Tardive dyskinesia: 3. Average change score (AIMS, high=poor) ‐ medium term.

Comparison 15 ENZYME INHIBITOR ‐ VMAT2 INHIBITORS versus PLACEBO, Outcome 3 Adverse events ‐ medium term.
Figuras y tablas -
Analysis 15.3

Comparison 15 ENZYME INHIBITOR ‐ VMAT2 INHIBITORS versus PLACEBO, Outcome 3 Adverse events ‐ medium term.

Comparison 15 ENZYME INHIBITOR ‐ VMAT2 INHIBITORS versus PLACEBO, Outcome 4 Leaving the study early ‐ medium term.
Figuras y tablas -
Analysis 15.4

Comparison 15 ENZYME INHIBITOR ‐ VMAT2 INHIBITORS versus PLACEBO, Outcome 4 Leaving the study early ‐ medium term.

Comparison 16 FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO, Outcome 1 Tardive dyskinesia: 2. No clinically important improvement ‐ medium term.
Figuras y tablas -
Analysis 16.1

Comparison 16 FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO, Outcome 1 Tardive dyskinesia: 2. No clinically important improvement ‐ medium term.

Comparison 16 FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO, Outcome 2 Mental state: deterioration ‐ medium term.
Figuras y tablas -
Analysis 16.2

Comparison 16 FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO, Outcome 2 Mental state: deterioration ‐ medium term.

Comparison 16 FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO, Outcome 3 Adverse events: Parkinsonism ‐ Average change in scale score (ESRS, low=better) ‐ medium term.
Figuras y tablas -
Analysis 16.3

Comparison 16 FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO, Outcome 3 Adverse events: Parkinsonism ‐ Average change in scale score (ESRS, low=better) ‐ medium term.

Comparison 16 FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO, Outcome 4 Adverse events: Dystonia ‐ Average change in scale score (ESRS, low=better) ‐ medium term.
Figuras y tablas -
Analysis 16.4

Comparison 16 FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO, Outcome 4 Adverse events: Dystonia ‐ Average change in scale score (ESRS, low=better) ‐ medium term.

Comparison 16 FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO, Outcome 5 Adverse events: Akathisia ‐ Average change in scale score (ESRS, low=better) ‐ medium term.
Figuras y tablas -
Analysis 16.5

Comparison 16 FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO, Outcome 5 Adverse events: Akathisia ‐ Average change in scale score (ESRS, low=better) ‐ medium term.

Comparison 16 FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO, Outcome 6 Leaving the study early ‐ medium term.
Figuras y tablas -
Analysis 16.6

Comparison 16 FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO, Outcome 6 Leaving the study early ‐ medium term.

Comparison 17 FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.
Figuras y tablas -
Analysis 17.1

Comparison 17 FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.

Comparison 17 FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.
Figuras y tablas -
Analysis 17.2

Comparison 17 FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.

Comparison 17 FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ medium term.
Figuras y tablas -
Analysis 17.3

Comparison 17 FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ medium term.

Comparison 17 FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO, Outcome 4 Tardive dyskinesia: 1. Average change in scale score (AIMS, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 17.4

Comparison 17 FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO, Outcome 4 Tardive dyskinesia: 1. Average change in scale score (AIMS, high=poor) ‐ medium term.

Comparison 17 FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO, Outcome 5 Mental state: 2. Average change in scale score (BPRS, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 17.5

Comparison 17 FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO, Outcome 5 Mental state: 2. Average change in scale score (BPRS, high=poor) ‐ medium term.

Comparison 17 FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO, Outcome 6 Leaving the study early ‐ medium term.
Figuras y tablas -
Analysis 17.6

Comparison 17 FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO, Outcome 6 Leaving the study early ‐ medium term.

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.
Figuras y tablas -
Analysis 18.1

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.
Figuras y tablas -
Analysis 18.2

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 18.3

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term.

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 4 Leaving the study early ‐ medium term.
Figuras y tablas -
Analysis 18.4

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 4 Leaving the study early ‐ medium term.

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 5 Mental state: deterioration ‐ medium term.
Figuras y tablas -
Analysis 18.5

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 5 Mental state: deterioration ‐ medium term.

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 6 Mental state: 1. Average endpoint scale score (PANSS total, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 18.6

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 6 Mental state: 1. Average endpoint scale score (PANSS total, high=poor) ‐ medium term.

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 7 Cognitive function: CPT‐37 ‐ proportion correct responses (high=better) ‐ medium term.
Figuras y tablas -
Analysis 18.7

Comparison 18 HERB ‐ GINKGO BILOBA versus PLACEBO, Outcome 7 Cognitive function: CPT‐37 ‐ proportion correct responses (high=better) ‐ medium term.

Comparison 19 HORMONE ‐ OESTROGEN versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term.
Figuras y tablas -
Analysis 19.1

Comparison 19 HORMONE ‐ OESTROGEN versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term.

Comparison 19 HORMONE ‐ OESTROGEN versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ short term.
Figuras y tablas -
Analysis 19.2

Comparison 19 HORMONE ‐ OESTROGEN versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ short term.

Comparison 19 HORMONE ‐ OESTROGEN versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ short term.
Figuras y tablas -
Analysis 19.3

Comparison 19 HORMONE ‐ OESTROGEN versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ short term.

Comparison 19 HORMONE ‐ OESTROGEN versus PLACEBO, Outcome 4 Tardive dyskinesia: 4. Average scale score (AIMS, high=poor) ‐ short term.
Figuras y tablas -
Analysis 19.4

Comparison 19 HORMONE ‐ OESTROGEN versus PLACEBO, Outcome 4 Tardive dyskinesia: 4. Average scale score (AIMS, high=poor) ‐ short term.

Comparison 19 HORMONE ‐ OESTROGEN versus PLACEBO, Outcome 5 Adverse effects ‐ short term.
Figuras y tablas -
Analysis 19.5

Comparison 19 HORMONE ‐ OESTROGEN versus PLACEBO, Outcome 5 Adverse effects ‐ short term.

Comparison 19 HORMONE ‐ OESTROGEN versus PLACEBO, Outcome 6 Leaving the study early ‐ short term.
Figuras y tablas -
Analysis 19.6

Comparison 19 HORMONE ‐ OESTROGEN versus PLACEBO, Outcome 6 Leaving the study early ‐ short term.

Comparison 20 HORMONE ‐ INSULIN versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.
Figuras y tablas -
Analysis 20.1

Comparison 20 HORMONE ‐ INSULIN versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.

Comparison 20 HORMONE ‐ INSULIN versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.
Figuras y tablas -
Analysis 20.2

Comparison 20 HORMONE ‐ INSULIN versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.

Comparison 20 HORMONE ‐ INSULIN versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ medium term.
Figuras y tablas -
Analysis 20.3

Comparison 20 HORMONE ‐ INSULIN versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ medium term.

Comparison 20 HORMONE ‐ INSULIN versus PLACEBO, Outcome 4 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 20.4

Comparison 20 HORMONE ‐ INSULIN versus PLACEBO, Outcome 4 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term.

Comparison 20 HORMONE ‐ INSULIN versus PLACEBO, Outcome 5 Leaving the study early ‐ medium term.
Figuras y tablas -
Analysis 20.5

Comparison 20 HORMONE ‐ INSULIN versus PLACEBO, Outcome 5 Leaving the study early ‐ medium term.

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement.
Figuras y tablas -
Analysis 21.1

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement.

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ short term.
Figuras y tablas -
Analysis 21.2

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ short term.

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ short term.
Figuras y tablas -
Analysis 21.3

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ short term.

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 4 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term.
Figuras y tablas -
Analysis 21.4

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 4 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term.

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 5 Adverse effects.
Figuras y tablas -
Analysis 21.5

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 5 Adverse effects.

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 6 Leaving the study early.
Figuras y tablas -
Analysis 21.6

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 6 Leaving the study early.

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 7 Cognitive function: Average scale score ‐ medium term.
Figuras y tablas -
Analysis 21.7

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 7 Cognitive function: Average scale score ‐ medium term.

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 8 Mental state: deterioration ‐ medium term.
Figuras y tablas -
Analysis 21.8

Comparison 21 HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT, Outcome 8 Mental state: deterioration ‐ medium term.

Comparison 22 MOOD STABILISER ‐ LITHIUM versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term.
Figuras y tablas -
Analysis 22.1

Comparison 22 MOOD STABILISER ‐ LITHIUM versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term.

Comparison 22 MOOD STABILISER ‐ LITHIUM versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ short term.
Figuras y tablas -
Analysis 22.2

Comparison 22 MOOD STABILISER ‐ LITHIUM versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ short term.

Comparison 22 MOOD STABILISER ‐ LITHIUM versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ short term.
Figuras y tablas -
Analysis 22.3

Comparison 22 MOOD STABILISER ‐ LITHIUM versus PLACEBO, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ short term.

Comparison 22 MOOD STABILISER ‐ LITHIUM versus PLACEBO, Outcome 4 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ short term.
Figuras y tablas -
Analysis 22.4

Comparison 22 MOOD STABILISER ‐ LITHIUM versus PLACEBO, Outcome 4 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ short term.

Comparison 22 MOOD STABILISER ‐ LITHIUM versus PLACEBO, Outcome 5 Adverse events ‐ short term.
Figuras y tablas -
Analysis 22.5

Comparison 22 MOOD STABILISER ‐ LITHIUM versus PLACEBO, Outcome 5 Adverse events ‐ short term.

Comparison 22 MOOD STABILISER ‐ LITHIUM versus PLACEBO, Outcome 6 Leaving the study early ‐ short term.
Figuras y tablas -
Analysis 22.6

Comparison 22 MOOD STABILISER ‐ LITHIUM versus PLACEBO, Outcome 6 Leaving the study early ‐ short term.

Comparison 23 POLYPEPTIDE ‐ CERULETIDE versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. Not any improvement.
Figuras y tablas -
Analysis 23.1

Comparison 23 POLYPEPTIDE ‐ CERULETIDE versus PLACEBO, Outcome 1 Tardive dyskinesia: 1. Not any improvement.

Comparison 23 POLYPEPTIDE ‐ CERULETIDE versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Deterioration.
Figuras y tablas -
Analysis 23.2

Comparison 23 POLYPEPTIDE ‐ CERULETIDE versus PLACEBO, Outcome 2 Tardive dyskinesia: 2. Deterioration.

Comparison 23 POLYPEPTIDE ‐ CERULETIDE versus PLACEBO, Outcome 3 Adverse effects.
Figuras y tablas -
Analysis 23.3

Comparison 23 POLYPEPTIDE ‐ CERULETIDE versus PLACEBO, Outcome 3 Adverse effects.

Comparison 23 POLYPEPTIDE ‐ CERULETIDE versus PLACEBO, Outcome 4 Leaving the study early ‐ medium term.
Figuras y tablas -
Analysis 23.4

Comparison 23 POLYPEPTIDE ‐ CERULETIDE versus PLACEBO, Outcome 4 Leaving the study early ‐ medium term.

Comparison 24 HYPNOSIS OR RELAXATION versus TREATMENT AS USUAL, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.
Figuras y tablas -
Analysis 24.1

Comparison 24 HYPNOSIS OR RELAXATION versus TREATMENT AS USUAL, Outcome 1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term.

Comparison 24 HYPNOSIS OR RELAXATION versus TREATMENT AS USUAL, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.
Figuras y tablas -
Analysis 24.2

Comparison 24 HYPNOSIS OR RELAXATION versus TREATMENT AS USUAL, Outcome 2 Tardive dyskinesia: 2. Not any improvement ‐ medium term.

Comparison 24 HYPNOSIS OR RELAXATION versus TREATMENT AS USUAL, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ medium term.
Figuras y tablas -
Analysis 24.3

Comparison 24 HYPNOSIS OR RELAXATION versus TREATMENT AS USUAL, Outcome 3 Tardive dyskinesia: 3. Deterioration ‐ medium term.

Comparison 24 HYPNOSIS OR RELAXATION versus TREATMENT AS USUAL, Outcome 4 Leaving the study early ‐ medium term.
Figuras y tablas -
Analysis 24.4

Comparison 24 HYPNOSIS OR RELAXATION versus TREATMENT AS USUAL, Outcome 4 Leaving the study early ‐ medium term.

Table 3. Suggestions for design of future study

Methods

Allocation: randomised, with sequence generation and concealment of allocation clearly described.
Blindness: double, tested.
Duration: 12 months beyond end of intervention at least.
Raters: independent.

Participants

People with antipsychotic‐induced tardive dyskinesia.*
Age: any.
Sex: both.
History: any.
N = 300.**

Interventions

1. Active intervention. N = 150.
2. Placebo: N = 150.

Outcomes

Tardive dyskinesia: any clinically important improvement in TD, any improvement, deterioration.***
Adverse effects: no clinically significant extrapyramidal adverse effects ‐ any time period***, use of any antiparkinsonism drugs, other important adverse events.
Leaving the study early.
Service outcomes: admitted, number of admissions, length of hospitalisation, contacts with psychiatric services.
Compliance with drugs.
Economic evaluations: cost‐effectiveness, cost‐benefit.
General state: relapse, frequency and intensity of minor and major exacerbations.
Social confidence, social inclusion, social networks, or personalised quality of life: binary measure
Distress among relatives: binary measure.
Burden on family: binary measure.

Notes

* This could be diagnosed by clinical decision. If funds were permitting all participants could be screened using operational criteria, otherwise a random sample should suffice.

** Size of study with sufficient power to highlight about a 10% difference between groups for primary outcome.
*** Primary outcome. The same applies to the measure of primary outcome as for diagnosis. Not everyone may need to have operational criteria applied if clinical impression is proved to be accurate.

Figuras y tablas -
Table 3. Suggestions for design of future study
Summary of findings for the main comparison. ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO for antipsychotic‐induced tardive dyskinesia

DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO for antipsychotic‐induced tardive dyskinesia

Patient or population: female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia
Settings: inpatients in Japan and the UK
Intervention: dihydrogenated ergot alkaloids (co‐dergocrine mesylate) (4.5 mg/day to 6 mg/day) versus placebo

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Placebo

DIHYDROGENATED ERGOT ALKALOIDS

Tardive dyskinesia: No clinically important improvement
follow‐up: 6 weeks

786 per 1000

354 per 1000
(165 to 762)

RR 0.45
(0.21 to 0.97)

28
(1 RCT)

⊕⊕⊝⊝
low1,2

Tardive dyskinesia: Deterioration of symptoms

follow‐up: 6 weeks

71 per 1000

24 per 1000
(1 to 539)

RR 0.33
(0.01 to 7.55)

28
(1 RCT)

⊕⊝⊝⊝
very low1,3

Adverse effects ‐ any adverse effect

follow‐up: 6 weeks

214 per 1000

499 per 1000
(161 to 1000)

RR 2.33
(0.75 to 7.23)

28
(1 RCT)

⊕⊝⊝⊝
very low1,3

Acceptability of treatment (measured by participants leaving the study early)

follow‐up: 6 weeks

42 per 1000

14 per 1000
(1 to 305)

RR 0.33
(0.02 to 7.32)

48
(2 RCTs)

⊕⊝⊝⊝
very low1,3,4

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported

This outcome was not reported.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Downgraded one step for risk of bias: randomisation procedure and allocation concealment were not adequately described.
2 Downgraded one step for imprecision: very small sample size and few events reported.
3 Downgraded two steps for imprecision: very small sample size and very few events reported with the 95% CI around the effect estimate indicating both appreciable benefit for dihydrogenated ergot alkaloids and no effect.
4 Downgraded one step for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability.

Figuras y tablas -
Summary of findings for the main comparison. ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Summary of findings 2. ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO for antipsychotic‐induced tardive dyskinesia

LEVETIRACETAM versus PLACEBO for antipsychotic‐induced tardive dyskinesia

Patient or population: female and male 47‐54 years old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia
Settings: in‐ and outpatients in Belgium, Bulgaria, and the USA
Intervention: levetiracetam (1500 mg twice per day) versus placebo

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Placebo

LEVETIRACETAM

Tardive dyskinesia: No clinically important improvement ‐ not reported

This outcome was not reported.

Tardive dyskinesia: Deterioration of symptoms ‐ not reported

This outcome was not reported.

Adverse effects ‐ any adverse effect

follow‐up: 8 weeks

457 per 1000

233 per 1000
(114 to 475)

RR 0.51
(0.25 to 1.04)

69
(1 RCT)

⊕⊕⊝⊝
low1,2

Acceptability of treatment (measured by participants leaving the study early)
follow‐up: 8‐12 weeks

167 per 1000

168 per 1000
(77 to 370)

RR 1.01
(0.46 to 2.22)

119
(2 RCTs)

⊕⊝⊝⊝
very low1,2,3

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported

This outcome was not reported.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Downgraded one step for risk of bias: randomisation procedure, allocation concealment and blinding were not adequately described.
2 Downgraded one step for imprecision: small sample size and few events reported with the 95% CI around the effect estimate indicating both appreciable benefit for levetiracetam and no effect.
3 Downgraded one step for inconsistency: substantial heterogeneity (I2 = 73%).

Figuras y tablas -
Summary of findings 2. ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Summary of findings 3. ANXIOLYTIC ‐ BUSPIRONE versus PLACEBO for antipsychotic‐induced tardive dyskinesia

BUSPIRONE versus PLACEBO for antipsychotic‐induced tardive dyskinesia

Patient or population: female and male 33‐year old (mean) patients with schizophrenia and antipsychotic‐induced tardive dyskinesia
Setting: inpatients, China
Intervention: Buspirone versus placebo.

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with placebo

Risk with buspirone

Tardive dyskinesia: No clinically important improvement
follow‐up: 6 weeks

905 per 1,000

480 per 1,000
(299 to 760)

RR 0.53
(0.33 to 0.84)

42
(1 RCT)

⊕⊕⊝⊝
low1,2

Tardive dyskinesia: Deterioration of symptoms ‐ not reported

This outcome was not reported.

Adverse effects ‐ not reported

This outcome was not reported.

Acceptability of treatment (measured by participants leaving the study early)
follow‐up: 6 weeks

not estimable

not estimable

RR not estimable

42
(1 RCT)

⊕⊝⊝⊝
very low1,3

No events were reported.

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported

This outcome was not reported.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 Downgraded one step for risk of bias: randomisation procedure, allocation concealment and blinding were not adequately described.

2 Downgraded one step for imprecision: very small sample size and few events reported.

3 Downgraded two steps for imprecision: effect could not be estimated due to very small sample size with no events reported.

Figuras y tablas -
Summary of findings 3. ANXIOLYTIC ‐ BUSPIRONE versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Summary of findings 4. ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) versus PLACEBO for antipsychotic‐induced tardive dyskinesia

VMAT2‐inhibitor compared to placebo for antipsychotic‐induced tardive dyskinesia

Patient or population: 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder + antipsychotic‐induced tardive dyskinesia
Settings: in‐ and outpatients in the USA
Intervention: Valbenazine (NBI‐98854) (25mg to 75mg/day) versus placebo

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Placebo

VMAT2‐inhibitor

Tardive dyskinesia: 1. No clinically important improvement
Follow‐up: 6 weeks

826 per 1000

520 per 1000
(380 to 710)

RR 0.63
(0.46 to 0.86)

92
(1 study)

⊕⊕⊕⊝
moderate1

Adverse effects ‐ any adverse effect
Follow‐up: 6 weeks

327 per 1000

490 per 1000
(300 to 800)

RR 1.50
(0.92 to 2.45)

100
(1 study)

⊕⊕⊝⊝
low2

Leaving the study early
follow‐up: 6 weeks

98 per 1000

98 per 1000
(30 to 319)

RR 1.00
(0.31 to 3.25)

102
(1 study)

⊕⊝⊝⊝
very low2,3

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Downgraded one step for imprecision: small sample size and few events reported
2 Downgraded two steps for serious imprecision: small sample size and very few events reported with the 95% CI around the effect estimate indicating both appreciable benefit for valbenazine and no effect.
3 Downgraded one step for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability.

Figuras y tablas -
Summary of findings 4. ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Summary of findings 5. FATTY ACID ‐ ETHYL‐EPA versus PLACEBO for antipsychotic‐induced tardive dyskinesia

ETHYL‐EPA versus PLACEBO for antipsychotic‐induced tardive dyskinesia

Patient or population: female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
Settings: in‐ and outpatients in South Africa
Intervention: ethyl‐EPA (omega‐3 fatty acid eicosapentaenoic acid derivative) versus placebo

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Placebo

ETHYL‐EPA

Tardive dyskinesia: No clinically important improvement ‐ not reported

This outcome was not reported.

Tardive dyskinesia: Deterioration of symptoms ‐ not reported

This outcome was not reported.

Adverse effects: EPS: parkinsonism

measured by average ESRS change scores

follow‐up: 12 weeks

mean: ‐1.1 (3.3)

The mean change in ESRS: parkinsonism scale score in the ethyl‐EPA group was
0.3 points higher
(1.17 lower to 1.77 higher)

MD 0.30

(‐1.17 to 1.77)

75

(1 RCT)

⊕⊕⊝⊝
low1,2

Adverse effects: EPS: dystonia

measured by average ESRS change scores

follow‐up: 12 weeks

mean: 0.4 (0.5)

The mean change in ESRS: dystonia scale score in the ethyl‐EPA group was
0.35 points lower
(0.58 to 0.12 lower)

MD ‐0.35

(‐0.58 to ‐0.12)

75

(1 RCT)

⊕⊕⊝⊝
low1,2

Adverse effects: EPS: akathisia

measured by average ESRS change scores

follow‐up: 12 weeks

mean: ‐0.06 (0.7)

The mean change in ESRS: akathisia scale score in the ethyl‐EPA group was
0.04 points lower
(0.3 lower to 0.22 higher)

MD ‐0.04

(‐0.30 to 0.22)

75

(1 RCT)

⊕⊝⊝⊝
very low1,3

Acceptability of treatment (measured by participants leaving the study early)

follow‐up: 12 weeks

548 per 1000

214 per 1000
(115 to 406)

RR 0. 57
(0.2 7 to 1.22)

84
(1 RCT)

⊕⊝⊝⊝
very low1,2,4

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported

This outcome was not reported.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; EPS: extrapyramidal symptoms; ESRS: Extrapyramidal Symptom Rating Scale; ethyl‐EPA: ethyl‐eicosapentaenoic acid; RCT: randomised controlled trial; RR: Risk ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Downgraded one step for risk of bias: randomisation procedure, allocation concealment and blinding were not adequately described.
2 Downgraded one step for imprecision: small sample size.
3 Downgraded two steps for serious imprecision: small sample size with the 95% CI around the effect estimate indicating both appreciable benefit for ethyl‐EPA and no effect.
4 Downgraded one step for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability.

Figuras y tablas -
Summary of findings 5. FATTY ACID ‐ ETHYL‐EPA versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Summary of findings 6. HERB ‐ GINKGO BILOBA versus PLACEBO for antipsychotic‐induced tardive dyskinesia

GINKGO BILOBA versus PLACEBO for antipsychotic‐induced tardive dyskinesia

Patient or population: male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia
Settings: inpatients in China
Intervention:GINKGO BILOBA (EGb‐761, standardised extract of Ginkgo biloba leaves) versus PLACEBO

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Placebo

GINKGO BILOBA

Tardive dyskinesia: No clinically important improvement
follow‐up: 12 weeks

987 per 1000

869 per 1000
(800 to 948)

RR 0.88
(0.81 to 0.96)

157
(1 RCT)

⊕⊕⊕⊝
moderate1

Tardive dyskinesia: Deterioration of symptoms ‐ not reported

This outcome was not reported.

Adverse effects ‐ not reported

This outcome was not reported.

Acceptability of treatment (measured by participants leaving the study early)
follow‐up: 12 weeks

51 per 1000

13 per 1000
(2 to 112)

RR 0.25
(0.03 to 2.22)

157
(1 RCT)

⊕⊝⊝⊝
very low2,3

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported

This outcome was not reported.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Downgraded one step for imprecision: small sample size and few events reported.
2 Downgraded two steps for serious imprecision: small sample size and very few events reported with the 95% CI around the effect estimate indicating both appreciable benefit for Ginkgo biloba and no effect.
3 Downgraded one step for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability.

Figuras y tablas -
Summary of findings 6. HERB ‐ GINKGO BILOBA versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Summary of findings 7. HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT for antipsychotic‐induced tardive dyskinesia

MELATONIN versus PLACEBO OR NO TREATMENT for antipsychotic‐induced tardive dyskinesia

Patient or population: female and male 28 to 91 years old patients with antipsychotic‐induced tardive dyskinesia
Settings: in‐ and outpatients in Israel and Venezuela
Intervention: melatonin (2‐20 mg/day) versus placebo or no treatment

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Placebo/no treatment

MELATONIN

Tardive dyskinesia: No clinically important improvement
follow‐up: 3‐12 weeks

1000 per 1000

890 per 1000
(710 to 1000)

RR 0.89
(0.71 to 1.12)

32
(2 RCTs)

⊕⊕⊝⊝
low1,2

Tardive dyskinesia: Deterioration of symptoms

follow‐up: 3 weeks

200 per 1000

44 per 1000
(2 to 810)

RR 0.22
(0.01 to 4.05)

19
(1 RCT)

⊕⊕⊝⊝
low3

Adverse effects

follow‐up: 3‐12 weeks

See comment

See comment

Not estimable

54
(3 RCTs)

⊕⊕⊝⊝
low3

No events were reported.

Acceptability of treatment (measured by participants leaving the study early)
follow‐up: 3‐12 weeks

See comment

See comment

Not estimable

54
(3 RCTs)

⊕⊝⊝⊝
very low3,4

No events were reported.

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported

This outcome was not reported.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Downgraded one step for inconsistency: substantial heterogeneity (I2 = 46%).
2 Downgraded one step for imprecision: small sample size and few events reported with the 95% CI around the effect estimate indicating both appreciable benefit for melatonin and no effect.
3 Downgraded two steps for imprecision: very small sample size and no or very few events reported.
4 Downgraded one step for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability.

Figuras y tablas -
Summary of findings 7. HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT for antipsychotic‐induced tardive dyskinesia
Summary of findings 8. POLYPEPTIDE ‐ CERULETIDE versus PLACEBO for antipsychotic‐induced tardive dyskinesia

CERULETIDE versus PLACEBO for antipsychotic‐induced tardive dyskinesia

Patient or population: female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia
Settings: in‐ and outpatients in Japan
Intervention: ceruletide (0.8 microgram/kg/week) versus placebo

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Placebo

CERULETIDE

Tardive dyskinesia: No clinically important improvement ‐ not reported

This outcome was not reported.

Tardive dyskinesia: Deterioration of symptoms

follow‐up: 4‐8 weeks

20 per 1000

19 per 1000
(3 to 133)

RR 0.97
(0.14 to 6.80)

103
(2 RCTs)

⊕⊕⊝⊝
low1,2

Adverse effects ‐ any adverse effect

follow‐up: 4‐8 weeks

233 per 1000

308 per 1000
(173 to 551)

RR 1.32
(0.74 to 2.36)

122
(2 RCTs)

⊕⊕⊝⊝
low1,2

Acceptability of treatment (measured by participants leaving the study early)

follow‐up: 8 weeks

214 per 1000

234 per 1000
(105 to 514)

RR 1.09
(0.49 to 2.40)

85
(1 RCT)

⊕⊝⊝⊝
very low1,2,3

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported

This outcome was not reported.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Downgraded one step for risk of bias: unclear methods of randomisation, blinding not assessed, and potential introduction of detection bias due to subjective nature of outcome assessments.
2 Downgraded one step for imprecision: the two included studies included only 132 participants and the 95% CI around the effect estimate indicated both appreciable benefit for ceruletide and no effect.

3 Downgraded one step for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability.

Figuras y tablas -
Summary of findings 8. POLYPEPTIDE ‐ CERULETIDE versus PLACEBO for antipsychotic‐induced tardive dyskinesia
Summary of findings 9. HYPNOSIS or RELAXATION versus TAU for antipsychotic‐induced tardive dyskinesia

HYPNOSIS OR RELAXATION versus TAU for antipsychotic‐induced tardive dyskinesia

Patients or population: female and male 35 (mean) years old patients with schizophrenia and tardive dyskinesia, acute extrapyramidal symptoms, and/or pseudoparkinsonism
Setting: outpatients in the USA
Interventions: hypnosis or relaxation (8 sessions) versus TAU

Outcomes

Anticipated absolute effects* (95% CI)

Relative effect
(95% CI)

№ of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Risk with TAU

Risk with hypnosis or relaxation

Tardive dyskinesia: No clinically important improvement
follow‐up: 8 weeks

1,000 per 1,000

450 per 1,000
(210 to 940)

RR 0.45
(0.21 to 0.94)

15
(1 RCT)

⊕⊝⊝⊝
very low1,2

Tardive dyskinesia: Deterioration of symptoms
follow‐up: 8 weeks

200 per 1,000

36 per 1,000
(2 to 762)

RR 0.18
(0.01 to 3.81)

15
(1 RCT)

⊕⊝⊝⊝
very low1,3

Adverse effects ‐ not reported

This outcome was not reported.

Acceptability of treatment (measured by participants leaving the study early)
follow‐up: 8 weeks

0 per 1,000

0 per 1,000
(0 to 0)

not estimable

15
(1 RCT)

⊕⊝⊝⊝
very low1,4

No events were reported.

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported

This outcome was not reported.

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio; TAU: treatment as usual

GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

1 Downgraded two steps for risk of bias: fully randomised sequence generation and blinding was not achieved.
2 Downgraded one step for imprecision: very small sample size.
3 Downgraded two steps for imprecision: 95% CI includes benefit for both intervention arms; very small sample size with few events reported.
4 Downgraded two steps for imprecision: effect could not be estimated due to very small sample size with no events reported.

Figuras y tablas -
Summary of findings 9. HYPNOSIS or RELAXATION versus TAU for antipsychotic‐induced tardive dyskinesia
Table 1. Other relevant reviews

Review

Citation

Anticholinergics

Bergman 2018a

Benzodiazepines

Bergman 2018

Calcium‐channel blockers

Essali 2011

Cholinergics

Tammenmaa 2002

GABAergic compounds

Alabed 2011

Neuroleptic medications (including dose reduction and cessation)

Soares‐Weiser 2006

Non‐neuroleptic compounds that impact on the dopamine and noradrenaline systems (catecholaminergics)

El‐Sayeh 2006

Vitamin E

Soares‐Weiser 2011

This review, Miscellaneous treatments

Figuras y tablas -
Table 1. Other relevant reviews
Table 2. Overview of study characteristics

Study

N and setting

Condition

Sex and age

Intervention and duration

Comparison

Outcomes

Bucci 1971

20 outpatients in the USA

schizophrenia + TD

F+M
45‐62 years

Isocarboxazid + AP
40 weeks

Procyclidine + AP

TD symptoms, AEs

Cai 1988

57 participants, setting not reported

TD

F+M
28‐59 years

L‐stepholidine + AP
8 weeks

Placebo + AP

TD symptoms, AEs, mental state

Castro 2011

13 in‐ and outpatients in Venezuela

various psychiatric conditions + TD

F+M
46‐75 years

Melatonin + AP
12 weeks

Placebo + AP

TD symptoms, AEs, mental state

Emsley 2006

84 in‐ and outpatients in South Africa

schizophrenia or schizoaffective disorder + TD

F+M
m = 42 years

Omega‐3 fatty acid + AP
12 weeks

Placebo + AP

TD symptoms, AEs, mental state

Gardos 1979

22 inpatients in the USA

schizophrenia, dementia + TD

F+M
32‐84 years

Papaverine + AP
6 weeks

TAU + AP

TD symptoms

Glazer 1985

12 outpatients in the USA

various psychiatric conditions + TD

F
50‐65 years

Oestrogen + AP
3 weeks

Placebo + AP

TD symptoms, AEs

Glover 1982

15 outpatients in the USA

schizophrenia + TD or EPS

F+M
m = 34.9 years

Hypnosis or relaxation + AP
8 sessions

TAU + AP

TD symptoms

Goff 1993

33 outpatients in the USA

TD

F+M
m = 49 years

Selengiline + AP
6 weeks

Placebo + AP

TD symptoms

Hajioff 1983

20 inpatients in the UK

various psychiatric conditions + TD

F+M
60‐92 years

Ergoloid mesylates + AP
6 weeks

Placebo + AP

TD symptoms

Kojima 1992

85 in‐ and outpatients in Japan

schizophrenia + TD

F+M
31‐75 years

Ceruletide + AP
6 weeks

Placebo + AP

TD symptoms, AEs

Koshino 1979

42 inpatients in Japan

various psychiatric conditions + TD

F+M
m = 56 years

Cyproheptadine + AP
4 weeks

Placebo + AP

TD symptoms, AEs

Koshino 1983

28 inpatients in Japan

schizophrenia + TD

F+M
m = 59 years

Ergoloid mesylates + AP
6 weeks

Placebo + AP

TD symptoms, AEs, mental state

Libov 2007

40 inpatients in Israel

schizophrenia or schizoaffective disorder + TD

F+M
26‐69 years

Piracetam + AP
4 weeks

Placebo + AP

TD symptoms, AEs, global state

Mackay 1980

11 inpatients in the UK

various psychiatric conditions + TD

NR
56‐70 years

Lithium + AP
5 weeks

Placebo + AP

TD symptoms, AEs

Matsunaga 1988

37 inpatients in Japan

various psychiatric conditions + TD

F+M
m = 59 years

Ceruletide + AP
4 weeks

Placebo + AP

TD symptoms, AEs

Meco 1989

10 inpatients in Italy

schizophrenia + TD

F+M
33‐72 years

Ritanserin + AP
4 weeks

Placebo + AP

TD symptoms, AEs, mental state

Mosnik 1997

18 in‐ and outpatients in the USA

schizophrenia + TD

M
28‐65 years

Phenylalanine + AP
1 day

Placebo + AP

Leaving the study early

Mouret 1991

20 inpatients in Morocco

schizophrenia + TD

F+M
20‐67 years

Insulin + AP
12 weeks

Placebo + AP

TD symptoms

O'Brien 2014

88 in‐ and outpatients in the USA

various psychiatric conditions + TD

NR
18‐85 years

NBI‐98854 (VMAT2 inhibitor valbenazine) + AP
6 weeks

Placebo + AP

TD symptoms, AEs

Rastogi 1982

40 inpatients in the UK

various psychiatric conditions + TD

F+M
m = 70 years

Ergoloid mesylates + AP
6 weeks

Placebo + AP

TD symptoms

Richardson 2003

52 in‐ and outpatients in the USA

various psychiatric conditions + TD

M
m = 45 years

Branched‐chain amino acids + AP
3 weeks

Placebo + AP

TD symptoms

Shamir 2000

19 inpatients in Israel

schizophrenia + TD

F+M
62‐91 years

Melatonin + AP
4 weeks

Placebo + AP

TD symptoms, AEs

Shamir 2001

22 inpatients in Israel

schizophrenia + TD

F+M
28‐82 years

Melatonin + AP
6 weeks

Placebo + AP

AEs

Shi 2009

76 inpatients in China

TD

F+M
m = 56 years

Melatonin + AP
12 weeks

TAU + AP

Cognitive function

UCB Pharma 2005

69 inpatients in Belgium and Bulgaria

TD

F+M
18‐80 years

Levetiracetam + AP
8 weeks

Placebo + AP

TD symptoms, AEs

Wolkin 1986

16 in‐ and outpatients in the USA

schizophrenia + TD

M
m = 54 years

Evening primrose oil + AP
6 weeks

Placebo + AP

TD symptoms, mental state

Woods 2008

50 outpatients in the USA

various psychiatric conditions + TD

F+M
m = 47 years

Levetiracetam + AP
12 weeks

Placebo + AP

TD symptoms, mental state

Yang 1999

34 inpatients in China

schizophrenia + TD

F+M
m = 50 years

Promethazine + AP
12 weeks

Placebo + AP

TD symptoms, AEs, mental state, global state

Zeng 1995

42 inpatients in China

schizophrenia + TD

F+M
m = 32.5 years

Buspirone + AP
6 weeks

Placebo + AP

TD symptoms

Zeng 1996

46 inpatients in China

schizophrenia + TD

F+M
m = 33 years

Pemoline + AP
6 weeks

Placebo + AP

TD symptoms

Zhang 2011

157 inpatients in China

schizophrenia + TD

M
m = 45 years

Ginkgo biloba + AP
12 weeks

Placebo + AP

TD symptoms, mental state, cognitive function

AE = adverse effects, AP = antipsychotics, EPS = extrapyramidal symptoms, F = female, M = male, m = mean, N = number, TAU = treatment as usual, TD = tardive dyskinesia

Figuras y tablas -
Table 2. Overview of study characteristics
Comparison 1. ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.21, 0.97]

2 Tardive dyskinesia: 2. Not any improvement ‐ medium term Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.5 [0.23, 1.09]

3 Tardive dyskinesia: 3. Deterioration ‐ medium term Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.33 [0.01, 7.55]

4 Tardive dyskinesia: 3. Average endpoint scale score (Simpson scale, high=poor) ‐ medium term Show forest plot

1

28

Mean Difference (IV, Fixed, 95% CI)

‐2.80 [‐12.25, 6.65]

5 Tardive dyskinesia: Average scale change scores (various scales, high=poor) ‐ medium term Show forest plot

2

59

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.31 [‐0.83, 0.20]

5.1 AIMS+RTDS

1

40

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.31 [‐0.93, 0.32]

5.2 ADS

1

19

Std. Mean Difference (IV, Fixed, 95% CI)

‐0.33 [‐1.24, 0.57]

6 Mental state: Deterioration ‐ medium term Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.5 [0.05, 4.90]

7 Adverse events ‐ medium term Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

2.33 [0.75, 7.23]

8 Leaving the study early ‐ medium term Show forest plot

2

48

Risk Ratio (M‐H, Fixed, 95% CI)

0.33 [0.02, 7.32]

Figuras y tablas -
Comparison 1. ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS versus PLACEBO
Comparison 2. ALKALOID ‐ L‐STEPHOLIDINE (SPD) versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term Show forest plot

1

57

Risk Ratio (M‐H, Fixed, 95% CI)

0.54 [0.35, 0.82]

2 Mental state: 1. Average endpoint scale score (BPRS, high=poor) ‐ medium term Show forest plot

1

20

Mean Difference (IV, Fixed, 95% CI)

‐4.5 [‐7.60, ‐1.40]

3 Adverse events: any adverse events ‐ medium term Show forest plot

1

57

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4 Leaving the study early ‐ medium term Show forest plot

1

57

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 2. ALKALOID ‐ L‐STEPHOLIDINE (SPD) versus PLACEBO
Comparison 3. ALKALOID ‐ PAPAVERINE versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term Show forest plot

1

22

Mean Difference (IV, Fixed, 95% CI)

0.51 [‐1.18, 2.20]

Figuras y tablas -
Comparison 3. ALKALOID ‐ PAPAVERINE versus PLACEBO
Comparison 4. AMINO ACID ‐ BRANCHED‐CHAIN AMINO ACID (BCAA) versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term Show forest plot

1

52

Risk Ratio (M‐H, Fixed, 95% CI)

0.79 [0.63, 1.00]

2 Tardive dyskinesia: 1. Not any improvement ‐ short term Show forest plot

1

52

Risk Ratio (M‐H, Fixed, 95% CI)

0.64 [0.36, 1.11]

3 Tardive dyskinesia: 2. Deterioration ‐ short term Show forest plot

1

36

Risk Ratio (M‐H, Fixed, 95% CI)

0.29 [0.07, 1.19]

4 Tardive dyskinesia: Average endpoint score (Simpson scale, high=poor) ‐ short term Show forest plot

1

41

Mean Difference (IV, Fixed, 95% CI)

‐92.9 [‐167.57, ‐18.23]

5 Leaving the study early ‐ short term Show forest plot

1

52

Risk Ratio (M‐H, Fixed, 95% CI)

0.84 [0.37, 1.92]

Figuras y tablas -
Comparison 4. AMINO ACID ‐ BRANCHED‐CHAIN AMINO ACID (BCAA) versus PLACEBO
Comparison 5. AMINO ACID ‐ PHENYLALANINE versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Leaving the study early ‐ short term Show forest plot

1

18

Risk Ratio (M‐H, Fixed, 95% CI)

2.45 [0.11, 53.25]

Figuras y tablas -
Comparison 5. AMINO ACID ‐ PHENYLALANINE versus PLACEBO
Comparison 6. ANTIDEPRESSANT (MAO‐B inhibitor) ‐ SELEGILINE versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term Show forest plot

1

33

Risk Ratio (M‐H, Fixed, 95% CI)

1.37 [0.96, 1.94]

2 Leaving the study early ‐ medium term Show forest plot

1

33

Risk Ratio (M‐H, Fixed, 95% CI)

10.39 [0.62, 173.97]

Figuras y tablas -
Comparison 6. ANTIDEPRESSANT (MAO‐B inhibitor) ‐ SELEGILINE versus PLACEBO
Comparison 7. ANTIDEPRESSANT (MAOI) ISOCARBOXAZID versus PROCYCLIDINE

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ long term Show forest plot

1

20

Risk Ratio (M‐H, Fixed, 95% CI)

0.24 [0.08, 0.71]

2 Tardive dyskinesia: 1. Not any improvement ‐ long term Show forest plot

1

20

Risk Ratio (M‐H, Fixed, 95% CI)

0.14 [0.03, 0.64]

3 Adverse effects ‐ long term Show forest plot

1

20

Risk Ratio (M‐H, Fixed, 95% CI)

3.0 [0.14, 65.90]

4 Leaving the study early ‐ long term Show forest plot

1

20

Risk Ratio (M‐H, Fixed, 95% CI)

3.0 [0.14, 65.90]

Figuras y tablas -
Comparison 7. ANTIDEPRESSANT (MAOI) ISOCARBOXAZID versus PROCYCLIDINE
Comparison 8. ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: No clinically important improvement (short term) Show forest plot

1

10

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.70, 1.43]

2 Tardive dyskinesia: Not any improvement (short term) Show forest plot

1

10

Risk Ratio (IV, Fixed, 95% CI)

0.28 [0.02, 4.66]

3 Tardive dyskinesia: Deterioration (short term) Show forest plot

1

10

Risk Ratio (IV, Fixed, 95% CI)

0.47 [0.02, 9.26]

4 Tardive dyskinesia: Average change score (AIMS, high=poor) (short term) Show forest plot

1

10

Mean Difference (IV, Fixed, 95% CI)

‐2.0 [‐5.93, 1.93]

5 General mental state: Deterioration (short term) Show forest plot

1

10

Risk Ratio (IV, Fixed, 95% CI)

0.47 [0.02, 9.26]

6 General mental state: Average change score (BPRS, high=poor) (short term) Show forest plot

1

10

Mean Difference (IV, Fixed, 95% CI)

‐0.80 [‐3.10, 1.50]

Figuras y tablas -
Comparison 8. ANTIDEPRESSANT (SSRI) ‐ RITANSERIN vs PLACEBO
Comparison 9. ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. Average endpoint score (AIMS, high=poor) ‐ medium term Show forest plot

1

50

Mean Difference (IV, Fixed, 95% CI)

‐2.18 [‐3.65, ‐0.71]

2 Tardive dyskinesia: 1. Average change score (hyperkinesia subscale of the SHRS , high=poor) ‐ medium term Show forest plot

1

69

Mean Difference (IV, Fixed, 95% CI)

0.13 [‐0.73, 0.99]

3 Leaving the study early ‐ medium term Show forest plot

2

119

Risk Ratio (M‐H, Fixed, 95% CI)

1.01 [0.46, 2.22]

4 Adverse effects ‐ medium term Show forest plot

1

69

Risk Ratio (M‐H, Fixed, 95% CI)

0.51 [0.25, 1.04]

5 Mental state: deterioration ‐ medium term Show forest plot

1

50

Risk Ratio (M‐H, Fixed, 95% CI)

0.67 [0.12, 3.65]

Figuras y tablas -
Comparison 9. ANTIEPILEPTIC ‐ LEVETIRACETAM versus PLACEBO
Comparison 10. ANTIHISTAMINE ‐ CYPROHEPTADINE versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 2. Not any improvement ‐ short term Show forest plot

1

42

Risk Ratio (M‐H, Fixed, 95% CI)

0.54 [0.27, 1.08]

2 Tardive dyskinesia: 3. Deterioration ‐ short term Show forest plot

1

42

Risk Ratio (M‐H, Fixed, 95% CI)

0.33 [0.01, 7.74]

3 Adverse events ‐ short term Show forest plot

1

42

Risk Ratio (M‐H, Fixed, 95% CI)

0.33 [0.04, 2.95]

4 Leaving the study early ‐ short term Show forest plot

1

42

Risk Ratio (M‐H, Fixed, 95% CI)

0.33 [0.01, 7.74]

Figuras y tablas -
Comparison 10. ANTIHISTAMINE ‐ CYPROHEPTADINE versus PLACEBO
Comparison 11. ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: No clinically important improvement (medium term) Show forest plot

1

34

Risk Ratio (M‐H, Fixed, 95% CI)

0.24 [0.11, 0.55]

2 Tardive dyskinesia: Not any improvement (medium term) Show forest plot

1

34

Risk Ratio (IV, Fixed, 95% CI)

0.06 [0.01, 0.43]

3 Tardive dyskinesia: Average endpoint score (AIMS, high=poor) (medium term) Show forest plot

1

34

Mean Difference (IV, Fixed, 95% CI)

‐7.10 [‐9.53, ‐4.67]

4 General mental state: Average endpoint score (BPRS, high=poor) (medium term) Show forest plot

1

34

Mean Difference (IV, Fixed, 95% CI)

0.70 [‐3.77, 5.17]

5 Adverse effects: Any adverse effects (TESS, high=poor) (medium term) Show forest plot

1

34

Mean Difference (IV, Fixed, 95% CI)

‐0.10 [‐0.53, 0.33]

6 Adverse effects: Parkinsonism ‐ Average endpoint score (RSESE) (medium term) Show forest plot

1

34

Mean Difference (IV, Fixed, 95% CI)

‐0.5 [‐1.36, 0.36]

7 Global state: Average endpoint score (CGI, high=poor) (medium term) Show forest plot

1

34

Mean Difference (IV, Fixed, 95% CI)

‐1.00 [‐3.78, ‐2.22]

Figuras y tablas -
Comparison 11. ANTIPSYCHOTIC ‐ PROMETHAZINE vs PLACEBO
Comparison 12. ANXIOLYTIC ‐ BUSPIRONE versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term Show forest plot

1

42

Risk Ratio (M‐H, Fixed, 95% CI)

0.53 [0.33, 0.84]

2 Tardive dyskinesia: 2. Not any improvement ‐ medium term Show forest plot

1

42

Risk Ratio (M‐H, Fixed, 95% CI)

0.33 [0.15, 0.75]

3 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term Show forest plot

1

42

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐1.45, 1.45]

4 Leaving the study early ‐ medium term Show forest plot

1

42

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 12. ANXIOLYTIC ‐ BUSPIRONE versus PLACEBO
Comparison 13. COGNITIVE ENHANCER ‐ PIRACETAM versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. Average endpoint score (ESRS, high=poor) ‐ short term Show forest plot

1

35

Mean Difference (IV, Fixed, 95% CI)

‐0.70 [‐4.30, 2.90]

2 Parkinsonism: 1. Average endpoint score (ESRS, high=poor) ‐ short term Show forest plot

1

35

Mean Difference (IV, Fixed, 95% CI)

2.5 [‐4.73, 9.73]

3 Leaving the study early ‐ short term Show forest plot

1

40

Risk Ratio (M‐H, Fixed, 95% CI)

0.23 [0.03, 1.85]

4 Global state: Average endpoint score (CGI, high=poor) ‐ short term Show forest plot

1

35

Mean Difference (IV, Fixed, 95% CI)

0.20 [‐0.35, 0.75]

Figuras y tablas -
Comparison 13. COGNITIVE ENHANCER ‐ PIRACETAM versus PLACEBO
Comparison 14. COGNITIVE ENHANCER/STIMULANT ‐ PEMOLINE versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term Show forest plot

1

46

Risk Ratio (M‐H, Fixed, 95% CI)

0.48 [0.29, 0.77]

2 Tardive dyskinesia: 2. Not any improvement ‐ medium term Show forest plot

1

46

Risk Ratio (M‐H, Fixed, 95% CI)

0.29 [0.13, 0.66]

3 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term Show forest plot

1

46

Mean Difference (IV, Fixed, 95% CI)

‐3.90 [‐5.47, ‐2.33]

4 Leaving the study early ‐ medium term Show forest plot

1

46

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 14. COGNITIVE ENHANCER/STIMULANT ‐ PEMOLINE versus PLACEBO
Comparison 15. ENZYME INHIBITOR ‐ VMAT2 INHIBITORS versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term Show forest plot

1

92

Risk Ratio (M‐H, Fixed, 95% CI)

0.63 [0.46, 0.86]

2 Tardive dyskinesia: 3. Average change score (AIMS, high=poor) ‐ medium term Show forest plot

1

89

Mean Difference (IV, Fixed, 95% CI)

‐2.5 [‐2.00, ‐1.00]

3 Adverse events ‐ medium term Show forest plot

1

100

Risk Ratio (M‐H, Fixed, 95% CI)

1.50 [0.92, 2.45]

4 Leaving the study early ‐ medium term Show forest plot

1

102

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.31, 3.25]

Figuras y tablas -
Comparison 15. ENZYME INHIBITOR ‐ VMAT2 INHIBITORS versus PLACEBO
Comparison 16. FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 2. No clinically important improvement ‐ medium term Show forest plot

1

75

Risk Ratio (M‐H, Fixed, 95% CI)

0.82 [0.57, 1.18]

2 Mental state: deterioration ‐ medium term Show forest plot

1

75

Risk Ratio (M‐H, Fixed, 95% CI)

0.49 [0.05, 5.14]

3 Adverse events: Parkinsonism ‐ Average change in scale score (ESRS, low=better) ‐ medium term Show forest plot

1

75

Mean Difference (IV, Fixed, 95% CI)

0.30 [‐1.17, 1.77]

4 Adverse events: Dystonia ‐ Average change in scale score (ESRS, low=better) ‐ medium term Show forest plot

1

75

Mean Difference (IV, Fixed, 95% CI)

‐0.35 [‐0.58, ‐0.12]

5 Adverse events: Akathisia ‐ Average change in scale score (ESRS, low=better) ‐ medium term Show forest plot

1

75

Mean Difference (IV, Fixed, 95% CI)

‐0.04 [‐0.30, 0.22]

6 Leaving the study early ‐ medium term Show forest plot

1

84

Risk Ratio (M‐H, Fixed, 95% CI)

0.57 [0.27, 1.22]

Figuras y tablas -
Comparison 16. FATTY ACID ‐ ETHYL EICOSAPENTAENOIC ACID versus PLACEBO
Comparison 17. FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term Show forest plot

1

16

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.69, 1.45]

2 Tardive dyskinesia: 2. Not any improvement ‐ medium term Show forest plot

1

16

Risk Ratio (M‐H, Fixed, 95% CI)

0.75 [0.24, 2.33]

3 Tardive dyskinesia: 3. Deterioration ‐ medium term Show forest plot

1

16

Risk Ratio (M‐H, Fixed, 95% CI)

1.5 [0.34, 6.70]

4 Tardive dyskinesia: 1. Average change in scale score (AIMS, high=poor) ‐ medium term Show forest plot

1

16

Mean Difference (IV, Fixed, 95% CI)

‐0.20 [‐3.10, 2.70]

5 Mental state: 2. Average change in scale score (BPRS, high=poor) ‐ medium term Show forest plot

1

10

Mean Difference (IV, Fixed, 95% CI)

‐6.0 [‐15.99, 3.99]

6 Leaving the study early ‐ medium term Show forest plot

1

16

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 17. FATTY ACID ‐ GAMMA‐LINOLENIC ACID versus PLACEBO
Comparison 18. HERB ‐ GINKGO BILOBA versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term Show forest plot

1

157

Risk Ratio (M‐H, Fixed, 95% CI)

0.88 [0.81, 0.96]

2 Tardive dyskinesia: 2. Not any improvement ‐ medium term Show forest plot

1

157

Risk Ratio (M‐H, Fixed, 95% CI)

0.51 [0.41, 0.65]

3 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term Show forest plot

1

157

Mean Difference (IV, Fixed, 95% CI)

‐2.06 [‐2.94, ‐1.18]

4 Leaving the study early ‐ medium term Show forest plot

1

157

Risk Ratio (M‐H, Fixed, 95% CI)

0.25 [0.03, 2.22]

5 Mental state: deterioration ‐ medium term Show forest plot

1

157

Risk Ratio (M‐H, Fixed, 95% CI)

0.34 [0.01, 8.16]

6 Mental state: 1. Average endpoint scale score (PANSS total, high=poor) ‐ medium term Show forest plot

1

157

Mean Difference (IV, Fixed, 95% CI)

‐3.30 [‐6.51, ‐0.09]

7 Cognitive function: CPT‐37 ‐ proportion correct responses (high=better) ‐ medium term Show forest plot

1

119

Mean Difference (IV, Fixed, 95% CI)

‐0.02 [‐0.10, 0.06]

Figuras y tablas -
Comparison 18. HERB ‐ GINKGO BILOBA versus PLACEBO
Comparison 19. HORMONE ‐ OESTROGEN versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term Show forest plot

1

12

Risk Ratio (M‐H, Fixed, 95% CI)

1.18 [0.76, 1.83]

2 Tardive dyskinesia: 2. Not any improvement ‐ short term Show forest plot

1

12

Risk Ratio (M‐H, Fixed, 95% CI)

0.33 [0.05, 2.37]

3 Tardive dyskinesia: 3. Deterioration ‐ short term Show forest plot

1

10

Risk Ratio (M‐H, Fixed, 95% CI)

0.2 [0.01, 3.35]

4 Tardive dyskinesia: 4. Average scale score (AIMS, high=poor) ‐ short term Show forest plot

1

10

Mean Difference (IV, Fixed, 95% CI)

‐1.2 [‐4.18, 1.78]

5 Adverse effects ‐ short term Show forest plot

1

12

Risk Ratio (M‐H, Fixed, 95% CI)

0.33 [0.02, 6.86]

6 Leaving the study early ‐ short term Show forest plot

1

12

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.08, 12.56]

Figuras y tablas -
Comparison 19. HORMONE ‐ OESTROGEN versus PLACEBO
Comparison 20. HORMONE ‐ INSULIN versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term Show forest plot

1

20

Risk Ratio (M‐H, Fixed, 95% CI)

0.52 [0.29, 0.96]

2 Tardive dyskinesia: 2. Not any improvement ‐ medium term Show forest plot

1

20

Risk Ratio (M‐H, Fixed, 95% CI)

0.06 [0.00, 0.90]

3 Tardive dyskinesia: 3. Deterioration ‐ medium term Show forest plot

1

20

Risk Ratio (M‐H, Fixed, 95% CI)

0.14 [0.01, 2.45]

4 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term Show forest plot

1

20

Mean Difference (IV, Fixed, 95% CI)

‐6.20 [‐10.53, ‐1.87]

5 Leaving the study early ‐ medium term Show forest plot

1

20

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 20. HORMONE ‐ INSULIN versus PLACEBO
Comparison 21. HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement Show forest plot

2

32

Risk Ratio (M‐H, Fixed, 95% CI)

0.89 [0.71, 1.12]

1.1 Short term

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.83, 1.21]

1.2 Medium term

1

13

Risk Ratio (M‐H, Fixed, 95% CI)

0.74 [0.44, 1.23]

2 Tardive dyskinesia: 2. Not any improvement ‐ short term Show forest plot

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

1.11 [0.47, 2.60]

3 Tardive dyskinesia: 3. Deterioration ‐ short term Show forest plot

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

0.22 [0.01, 4.05]

4 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ medium term Show forest plot

1

13

Mean Difference (IV, Fixed, 95% CI)

‐2.38 [‐6.58, 1.82]

5 Adverse effects Show forest plot

3

54

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.1 Short term

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 Medium term

2

35

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

6 Leaving the study early Show forest plot

3

54

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.1 Short term

1

19

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Medium term

2

35

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

7 Cognitive function: Average scale score ‐ medium term Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

7.1 WAIS

1

76

Mean Difference (IV, Fixed, 95% CI)

15.83 [4.61, 27.05]

7.2 WMS

1

76

Mean Difference (IV, Fixed, 95% CI)

3.77 [‐8.21, 15.75]

8 Mental state: deterioration ‐ medium term Show forest plot

1

13

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 21. HORMONE ‐ MELATONIN versus PLACEBO OR NO TREATMENT
Comparison 22. MOOD STABILISER ‐ LITHIUM versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ short term Show forest plot

1

11

Risk Ratio (M‐H, Fixed, 95% CI)

1.59 [0.79, 3.23]

2 Tardive dyskinesia: 2. Not any improvement ‐ short term Show forest plot

1

11

Risk Ratio (M‐H, Fixed, 95% CI)

4.29 [0.25, 72.90]

3 Tardive dyskinesia: 3. Deterioration ‐ short term Show forest plot

1

11

Risk Ratio (M‐H, Fixed, 95% CI)

4.29 [0.25, 72.90]

4 Tardive dyskinesia: 3. Average scale score (AIMS, high=poor) ‐ short term Show forest plot

1

11

Mean Difference (IV, Fixed, 95% CI)

0.63 [‐5.23, 6.49]

5 Adverse events ‐ short term Show forest plot

1

11

Risk Ratio (M‐H, Fixed, 95% CI)

6.0 [0.38, 94.35]

6 Leaving the study early ‐ short term Show forest plot

1

11

Risk Ratio (M‐H, Fixed, 95% CI)

2.57 [0.13, 52.12]

Figuras y tablas -
Comparison 22. MOOD STABILISER ‐ LITHIUM versus PLACEBO
Comparison 23. POLYPEPTIDE ‐ CERULETIDE versus PLACEBO

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. Not any improvement Show forest plot

2

132

Risk Ratio (M‐H, Fixed, 95% CI)

0.83 [0.65, 1.07]

1.1 Short term

1

47

Risk Ratio (M‐H, Fixed, 95% CI)

0.73 [0.50, 1.06]

1.2 Medium term

1

85

Risk Ratio (M‐H, Fixed, 95% CI)

0.90 [0.64, 1.27]

2 Tardive dyskinesia: 2. Deterioration Show forest plot

2

103

Risk Ratio (M‐H, Fixed, 95% CI)

0.97 [0.14, 6.80]

2.1 Short term

1

37

Risk Ratio (M‐H, Fixed, 95% CI)

2.85 [0.12, 65.74]

2.2 Medium term

1

66

Risk Ratio (M‐H, Fixed, 95% CI)

0.33 [0.01, 7.90]

3 Adverse effects Show forest plot

2

122

Risk Ratio (M‐H, Fixed, 95% CI)

1.32 [0.74, 2.36]

3.1 Short term

1

37

Risk Ratio (M‐H, Fixed, 95% CI)

3.79 [0.47, 30.77]

3.2 Medium term

1

85

Risk Ratio (M‐H, Fixed, 95% CI)

1.13 [0.61, 2.07]

4 Leaving the study early ‐ medium term Show forest plot

1

85

Risk Ratio (M‐H, Fixed, 95% CI)

1.09 [0.49, 2.40]

Figuras y tablas -
Comparison 23. POLYPEPTIDE ‐ CERULETIDE versus PLACEBO
Comparison 24. HYPNOSIS OR RELAXATION versus TREATMENT AS USUAL

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Tardive dyskinesia: 1. No clinically important improvement ‐ medium term Show forest plot

1

15

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.21, 0.94]

2 Tardive dyskinesia: 2. Not any improvement ‐ medium term Show forest plot

1

15

Risk Ratio (M‐H, Fixed, 95% CI)

0.18 [0.01, 3.81]

3 Tardive dyskinesia: 3. Deterioration ‐ medium term Show forest plot

1

15

Risk Ratio (M‐H, Fixed, 95% CI)

0.18 [0.01, 3.81]

4 Leaving the study early ‐ medium term Show forest plot

1

15

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.1 Short term

1

15

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 24. HYPNOSIS OR RELAXATION versus TREATMENT AS USUAL